Our policy at Mount Sinai Hospital is that for every percutaneous coronary intervention (PCI), we open the Runthrough NS. It is at 100% use in our interventions.
Dr. Sachar presented 12-month data from the RANGER II SFA trial of the Ranger drug-coated balloon (DCB) (Boston Scientific) on November 5th at the 2019 Vascular InterVentional Advances (VIVA) conference in Las Vegas, Nevada.